For the year ending 2025-12-31, PACB had $7,667K increase in cash & cash equivalents over the period. -$113,923K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -546,376 |
| Depreciation | 12,987 |
| Amortization of intangible assets | 369,448 |
| Amortization of right-of-use assets | 3,977 |
| Share-based compensation expense | 41,668 |
| Impairment charges | 15,000 |
| Merger-related compensation expense | 0 |
| Loss on extinguishment of debt | 0 |
| Gain on debt restructuring | 0 |
| Accretion of discount and amortization of premium on marketable securities, net | 4,365 |
| Change in fair value of contingent consideration | -18,700 |
| Inventory provision | 9,568 |
| Deferred income taxes | -546 |
| Other | -1,688 |
| Accounts receivable, net | 7,924 |
| Inventory, net | 1,419 |
| Prepaid expenses and other assets | -8,514 |
| Accounts payable | 2,482 |
| Accrued expenses | 3,158 |
| Deferred revenue | 101 |
| Operating lease liabilities | 723 |
| Contingent consideration liability | 0 |
| Other liabilities | -1,193 |
| Net cash used in operating activities | -111,209 |
| Purchase of property and equipment | 2,714 |
| Purchase of intangible assets | 5,000 |
| Cash paid for purchases of acquired entities, net of cash acquired | 0 |
| Purchase of investments | 216,911 |
| Sales of investments | 0 |
| Maturities of investments | 340,073 |
| Net cash provided by investing activities | 115,448 |
| Proceeds from issuance of common stock under equity offerings, net of issuance costs | 0 |
| Proceeds from issuance of common stock from equity plans | 3,428 |
| Payment of debt issuance costs | 0 |
| Payment of contingent consideration | 0 |
| Payments made in conjunction with convertible notes exchange | 0 |
| Notes payable principal payoff | 0 |
| Net cash provided by (used in) financing activities | 3,428 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 7,667 |
| Cash, cash equivalents, and restricted cash at beginning of period | 57,592 |
| Cash, cash equivalents, and restricted cash at end of period | 65,259 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)